RxDoctor Payments Data

Amy Zellers, DO

Family Medicine · Harrisburg, PANPI 1396937256

Payments from drug & device makers

$12,359in general payments, 2019–2025

Across 762 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • GSK$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$968
  • Lilly USA, LLC$850
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$12,320100%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk115$1,781
AbbVie(2 entities)84$1,434
GSK104$1,307
AstraZeneca58$1,191
Boehringer Ingelheim57$968
Lilly USA, LLC48$850
Pfizer59$584
Amgen24$439
Amarin Pharma, Inc.20$324
Exact Sciences14$271
Johnson & Johnson16$244
E.r. Squibb & Sons, L.L.C.11$202
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$195
Takeda Pharmaceuticals U.S.A., Inc.12$179
Otsuka America Pharmaceutical, Inc.9$173
Merck11$171
Dexcom, Inc.7$159
Novartis7$146
Astellas Pharma US Inc7$133
Sanofi Pasteur Inc.6$131
Abbott6$130
Mylan Specialty L.p.4$101
Aimmune Therapeutics, Inc.6$94
Nestle Healthcare Nutrition Inc.6$83
Vanda Pharmaceuticals Inc.3$74
IBSA Pharma Inc.4$74
Lundbeck LLC3$68
Teva Pharmaceuticals USA, Inc.4$67
Eisai Inc.2$66
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$65
Biohaven Pharmaceuticals, Inc.3$46
Regeneron Healthcare Solutions, Inc.2$42
Biohaven Pharmaceutical Holding Company Ltd.2$42
Axsome Therapeutics, Inc.1$34
Esperion Therapeutics, Inc.2$34
Xeris Pharmaceuticals, Inc.2$33
Harmony Biosciences LLC2$31
Cequr Corporation2$31
Cumberland Pharmaceuticals, Inc.2$31
Phathom Pharmaceuticals, Inc.3$30
Genentech USA, Inc.2$26
Kowa Pharmaceuticals America, Inc.2$23
Viatris Specialty LLC1$23
Bayer1$21
Verona Pharma, Inc.1$21
Mannkind Corporation1$20
Medtronic1$19
Inspire Medical Systems, Inc.1$18
Sumitomo Pharma America, Inc.1$18
Biogen1$18
Ironwood Pharmaceuticals, Inc1$18
Almatica Pharma LLC1$16
Radius Health, Inc.1$16
Idorsia Pharmaceuticals US Inc1$16
OPKO Pharmaceuticals, LLC1$12
Zyla Life Sciences, Inc.1$11
Bardy Diagnostics, Inc.1$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,359 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$110,608
Medicare patients
228
Services billed
1,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter103$84,323
EliquisApixaban60$69,272
TrulicityDulaglutide34$55,818
OzempicSemaglutide40$54,414
FarxigaDapagliflozin Propanediol75$51,611
MounjaroTirzepatide37$46,332
JardianceEmpagliflozin57$38,113
Humalog Kwikpen U-200Insulin Lispro11$12,247
Breo ElliptaFluticasone/Vilanterol17$10,177
RybelsusSemaglutide12$10,049
InvokanaCanagliflozin11$9,585
MyrbetriqMirabegron12$8,594
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,903
Rosuvastatin Calcium215$4,373
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,307$104,795146 claims
Lilly USA, LLCTrulicity, Mounjaro$850$102,15071 claims
PfizerEliquis$584$69,27260 claims
Novo NordiskOzempic, Rybelsus$1,781$64,46352 claims
AstraZenecaFarxiga$1,191$51,61175 claims
Boehringer IngelheimJardiance$968$38,11357 claims
Johnson & JohnsonInvokana$244$9,58511 claims
Astellas Pharma US IncMyrbetriq$133$8,59412 claims
Almatica Pharma LLCSertraline Hcl$16$1,279125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →